{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:21:43Z","timestamp":1792466503617,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41584-018-0006-8","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T13:25:07Z","timestamp":1526045107000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison"],"prefix":"10.1038","volume":"14","author":[{"given":"Joy","family":"Feld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M. et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70, 25\u201331 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/art.1780270301","volume":"27","author":"SM Linden van der","year":"1984","unstructured":"van der Linden, S. M., Valkenburg, H. A., de Jongh, B. M. & Cats, A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 27, 241\u2013249 (1984).","journal-title":"Arthritis Rheum."},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 374, 2563\u20132574 (2016).","journal-title":"N. Engl. J. Med."},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll, J. M. & Wright, V. Psoriatic arthritis. Semin. Arthritis Rheum. 3, 55\u201378 (1973).","journal-title":"Semin. Arthritis Rheum."},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin, C. T. et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68, 1387\u20131394 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR6","first-page":"974","volume":"32","author":"WJ Taylor","year":"2005","unstructured":"Taylor, W. J., Zmierczak, H. G. & Helliwell, P. S. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J. Rheumatol. 32, 974\u2013977 (2005).","journal-title":"J. Rheumatol."},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","volume":"9","author":"DD Gladman","year":"2007","unstructured":"Gladman, D. D. Axial disease in psoriatic arthritis. Curr. Rheumatol. Rep. 9, 455\u2013460 (2007).","journal-title":"Curr. Rheumatol. Rep."},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3899\/jrheum.091059","volume":"37","author":"V Chandran","year":"2010","unstructured":"Chandran, V., Tolusso, D. C., Cook, R. J. & Gladman, D. D. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J. Rheumatol. 37, 809\u2013815 (2010).","journal-title":"J. Rheumatol."},{"key":"6_CR9","first-page":"S31","volume":"33","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos, X., Coates, L. C. & Braun, J. The involvement of the spine in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S31\u201335 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","volume":"30","author":"JC Torre Alonso","year":"1991","unstructured":"Torre Alonso, J. C. et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. 30, 245\u2013250 (1991).","journal-title":"Br. J. Rheumatol."},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1468-3083.2011.03985.x","volume":"25","author":"Q Yang","year":"2011","unstructured":"Yang, Q. et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 25, 1409\u20131414 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"6_CR12","first-page":"279","volume":"12","author":"M Moghaddassi","year":"2009","unstructured":"Moghaddassi, M., Shahram, F., Chams-Davatchi, C., Najafizadeh, S. R. & Davatchi, F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch. Iran. Med. 12, 279\u2013283 (2009).","journal-title":"Arch. Iran. Med."},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/art.34536","volume":"64","author":"LC Coates","year":"2012","unstructured":"Coates, L. C. et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 64, 3150\u20133155 (2012).","journal-title":"Arthritis Rheum."},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1756-185X.2012.01736.x","volume":"15","author":"L Niccoli","year":"2012","unstructured":"Niccoli, L. et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int. J. Rheum. Dis. 15, 414\u2013418 (2012).","journal-title":"Int. J. Rheum. Dis."},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/03009740802609558","volume":"38","author":"JC Nossent","year":"2009","unstructured":"Nossent, J. C. & Gran, J. T. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand. J. Rheumatol. 38, 251\u2013255 (2009).","journal-title":"Scand. J. Rheumatol."},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheum."},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3899\/jrheum.090412","volume":"36","author":"V Chandran","year":"2009","unstructured":"Chandran, V., Barrett, J., Schentag, C. T., Farewell, V. T. & Gladman, D. D. Axial psoriatic arthritis: update on a longterm prospective study. J. Rheumatol. 36, 2744\u20132750 (2009).","journal-title":"J. Rheumatol."},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/ard.47.5.386","volume":"47","author":"JG Hanly","year":"1988","unstructured":"Hanly, J. G., Russell, M. L. & Gladman, D. D. Psoriatic spondyloarthropathy: a long term prospective study. Ann. Rheum. Dis. 47, 386\u2013393 (1988).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s100670200003","volume":"21","author":"R Queiro","year":"2002","unstructured":"Queiro, R. et al. Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Clin. Rheumatol. 21, 10\u201313 (2002).","journal-title":"Clin. Rheumatol."},{"key":"6_CR20","first-page":"1","volume":"16","author":"DD Gladman","year":"1993","unstructured":"Gladman, D. D., Brubacher, B., Buskila, D., Langevitz, P. & Farewell, V. T. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin. Invest. Med. 16, 1\u20137 (1993).","journal-title":"Clin. Invest. Med."},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3899\/jrheum.150634","volume":"93","author":"E Lubrano","year":"2015","unstructured":"Lubrano, E. et al. The definition and measurement of axial psoriatic arthritis. J. Rheumatol. Suppl. 93, 40\u201342 (2015).","journal-title":"J. Rheumatol. Suppl."},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10067-012-1990-8","volume":"31","author":"E Lubrano","year":"2012","unstructured":"Lubrano, E. & Spadaro, A. Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease? Clin. Rheumatol. 31, 1027\u20131032 (2012).","journal-title":"Clin. Rheumatol."},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","volume":"76","author":"DR Jadon","year":"2017","unstructured":"Jadon, D. R. et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann. Rheum. Dis. 76, 701\u2013707 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-015-0627-0","volume":"17","author":"S Exarchou","year":"2015","unstructured":"Exarchou, S. et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res. Ther. 17, 118 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"A Cortes","year":"2013","unstructured":"Cortes, A. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730\u2013738 (2013).","journal-title":"Nat. Genet."},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/BOR.0000000000000297","volume":"28","author":"DD O\u2019Rielly","year":"2016","unstructured":"O\u2019Rielly, D. D., Uddin, M. & Rahman, P. Ankylosing spondylitis: beyond genome-wide association studies. Curr. Opin. Rheumatol. 28, 337\u2013345 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","volume":"12","author":"MA Brown","year":"2016","unstructured":"Brown, M. A., Kenna, T. & Wordsworth, B. P. Genetics of ankylosing spondylitis \u2014 insights into pathogenesis. Nat. Rev. Rheumatol. 12, 81\u201391 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0889-857X(05)70045-4","volume":"24","author":"P Wordsworth","year":"1998","unstructured":"Wordsworth, P. Genes in the spondyloarthropathies. Rheum. Dis. Clin. North Am. 24, 845\u2013863 (1998).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"6_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep10314","volume":"5","author":"M Uddin","year":"2015","unstructured":"Uddin, M. et al. Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways. Sci. Rep. 5, 10314 (2015).","journal-title":"Sci. Rep."},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/rheumatology\/keu388","volume":"54","author":"I Essers","year":"2015","unstructured":"Essers, I. et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology 54, 633\u2013640 (2015).","journal-title":"Rheumatology"},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/annrheumdis-2012-202922","volume":"72","author":"P Machado","year":"2013","unstructured":"Machado, P. et al. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Ann. Rheum. Dis. 72, 1104\u20131107 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrg3502","volume":"14","author":"M Parkes","year":"2013","unstructured":"Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661\u2013673 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran, V. & Raychaudhuri, S. P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J. Autoimmun. 34, J314\u2013321 (2010).","journal-title":"J. Autoimmun."},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic Arthritis. N. Engl. J. Med. 376, 957\u2013970 (2017).","journal-title":"N. Engl. J. Med."},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00595700","volume":"247","author":"R Ananthakrishnan","year":"1973","unstructured":"Ananthakrishnan, R., Eckes, L. & Walter, H. On the genetics of psoriasis. An analysis of Hellgren\u2019s data for a model of multifactorial inheritance. Arch. Dermatol. Forsch. 247, 53\u201358 (1973).","journal-title":"Arch. Dermatol. Forsch."},{"key":"6_CR36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2340\/0001555562229236","volume":"62","author":"F Brandrup","year":"1982","unstructured":"Brandrup, F., Holm, N., Grunnet, N., Henningsen, K. & Hansen, H. E. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 62, 229\u2013236 (1982).","journal-title":"Acta Derm. Venereol."},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12375","volume":"169","author":"AS Lonnberg","year":"2013","unstructured":"Lonnberg, A. S. et al. Heritability of psoriasis in a large twin sample. Br. J. Dermatol. 169, 412\u2013416 (2013).","journal-title":"Br. J. Dermatol."},{"key":"6_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/rheumatology\/keh589","volume":"44","author":"A Myers","year":"2005","unstructured":"Myers, A., Kay, L. J., Lynch, S. A. & Walker, D. J. Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology 44, 773\u2013776 (2005).","journal-title":"Rheumatology"},{"key":"6_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/ard.2008.089367","volume":"68","author":"V Chandran","year":"2009","unstructured":"Chandran, V. et al. Familial aggregation of psoriatic arthritis. Ann. Rheum. Dis. 68, 664\u2013667 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR40","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/rheumatology\/kep243","volume":"48","author":"A Karason","year":"2009","unstructured":"Karason, A., Love, T. J. & Gudbjornsson, B. A strong heritability of psoriatic arthritis over four generations \u2014 the Reykjavik Psoriatic Arthritis Study. Rheumatology 48, 1424\u20131428 (2009).","journal-title":"Rheumatology"},{"key":"6_CR41","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/art.33415","volume":"64","author":"R Winchester","year":"2012","unstructured":"Winchester, R. et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 64, 1134\u20131144 (2012).","journal-title":"Arthritis Rheum."},{"key":"6_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/BOR.0000000000000136","volume":"27","author":"L Eder","year":"2015","unstructured":"Eder, L., Chandran, V. & Gladman, D. D. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr. Opin. Rheumatol. 27, 91\u201398 (2015).","journal-title":"Curr. Opin. Rheumatol."},{"key":"6_CR43","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.humimm.2013.07.014","volume":"74","author":"V Chandran","year":"2013","unstructured":"Chandran, V. et al. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum. Immunol. 74, 1333\u20131338 (2013).","journal-title":"Hum. Immunol."},{"key":"6_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/ard.2011.155044","volume":"71","author":"L Eder","year":"2012","unstructured":"Eder, L. et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 71, 50\u201355 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR45","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1186\/ar2097","volume":"8","author":"R Queiro","year":"2006","unstructured":"Queiro, R. et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res. Ther. 8, R185 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"6_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O FitzGerald","year":"2015","unstructured":"FitzGerald, O., Haroon, M., Giles, J. T. & Winchester, R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res. Ther. 17, 115 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"6_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ng.2827","volume":"46","author":"H Tang","year":"2014","unstructured":"Tang, H. et al. A large-scale screen for coding variants predisposing to psoriasis. Nat. Genet. 46, 45\u201350 (2014).","journal-title":"Nat. Genet."},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ng.689","volume":"42","author":"E Ellinghaus","year":"2010","unstructured":"Ellinghaus, E. et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42, 991\u2013995 (2010).","journal-title":"Nat. Genet."},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273\u2013290 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"6_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000041","volume":"4","author":"Y Liu","year":"2008","unstructured":"Liu, Y. et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4, e1000041 (2008).","journal-title":"PLoS Genet."},{"key":"6_CR51","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.688","volume":"42","author":"U Huffmeier","year":"2010","unstructured":"Huffmeier, U. et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42, 996\u2013999 (2010).","journal-title":"Nat. Genet."},{"key":"6_CR52","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/jid.2011.415","volume":"132","author":"E Ellinghaus","year":"2012","unstructured":"Ellinghaus, E. et al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J. Invest. Dermatol. 132, 1133\u20131140 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"6_CR53","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","volume":"97","author":"PE Stuart","year":"2015","unstructured":"Stuart, P. E. et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am. J. Hum. Genet. 97, 816\u2013836 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"6_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier, L. L. NK cell recognition. Annu. Rev. Immunol. 23, 225\u2013274 (2005).","journal-title":"Annu. Rev. Immunol."},{"key":"6_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/rheumatology\/ket296","volume":"53","author":"V Chandran","year":"2014","unstructured":"Chandran, V. et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology 53, 233\u2013239 (2014).","journal-title":"Rheumatology"},{"key":"6_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/annrheumdis-2012-201403","volume":"72","author":"MH Weisman","year":"2013","unstructured":"Weisman, M. H., Witter, J. P. & Reveille, J. D. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009\u20132010. Ann. Rheum. Dis. 72, 369\u2013373 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR57","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3899\/jrheum.140182","volume":"41","author":"PJ Mease","year":"2014","unstructured":"Mease, P. J., Garg, A., Helliwell, P. S., Park, J. J. & Gladman, D. D. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 annual meeting. J. Rheumatol. 41, 1249\u20131251 (2014).","journal-title":"J. Rheumatol."},{"key":"6_CR58","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jbspin.2007.11.005","volume":"75","author":"R Queiro","year":"2008","unstructured":"Queiro, R. et al. Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. Joint Bone Spine 75, 544\u2013547 (2008).","journal-title":"Joint Bone Spine"},{"key":"6_CR59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/ard.57.3.135","volume":"57","author":"PS Helliwell","year":"1998","unstructured":"Helliwell, P. S., Hickling, P. & Wright, V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann. Rheum. Dis. 57, 135\u2013140 (1998).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-0960-8","volume":"17","author":"U Lindstrom","year":"2016","unstructured":"Lindstrom, U. et al. Back pain and health status in patients with clinically diagnosed ankylosing spondylitis, psoriatic arthritis and other spondyloarthritis: a cross-sectional population-based study. BMC Musculoskelet. Disord. 17, 106 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"6_CR61","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3899\/jrheum.101049","volume":"38","author":"R Perez Alamino","year":"2011","unstructured":"Perez Alamino, R. et al. Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease. J. Rheumatol. 38, 1656\u20131660 (2011).","journal-title":"J. Rheumatol."},{"key":"6_CR62","first-page":"371","volume":"15","author":"DD Gladman","year":"1992","unstructured":"Gladman, D. D., Brubacher, B., Buskila, D., Langevitz, P. & Farewell, V. T. Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. Clin. Invest. Med. 15, 371\u2013375 (1992).","journal-title":"Clin. Invest. Med."},{"key":"6_CR63","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005652","volume":"95","author":"M Landi","year":"2016","unstructured":"Landi, M. et al. Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine 95, e5652 (2016).","journal-title":"Medicine"},{"key":"6_CR64","first-page":"1733","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman, D. D. et al. International spondyloarthritis interobserver reliability exercise \u2014 the INSPIRE study: I. Assessment of spinal measures. J. Rheumatol. 34, 1733\u20131739 (2007).","journal-title":"J. Rheumatol."},{"key":"6_CR65","first-page":"S44","volume":"33","author":"PS Helliwell","year":"2015","unstructured":"Helliwell, P. S. Assessment of disease activity in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S44\u2013S47 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"6_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/art.20421","volume":"51","author":"WJ Taylor","year":"2004","unstructured":"Taylor, W. J. & Harrison, A. A. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum. 51, 311\u2013315 (2004).","journal-title":"Arthritis Rheum."},{"key":"6_CR67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.20017","volume":"62","author":"JL Fernandez-Sueiro","year":"2010","unstructured":"Fernandez-Sueiro, J. L. et al. Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res. 62, 78\u201385 (2010).","journal-title":"Arthritis Care Res."},{"key":"6_CR68","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai, A. M. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann. Rheum. Dis. 76, 673\u2013680 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR69","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1136\/ard.2010.129726","volume":"69","author":"L Eder","year":"2010","unstructured":"Eder, L., Chandran, V., Shen, H., Cook, R. J. & Gladman, D. D. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann. Rheum. Dis. 69, 2160\u20132164 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR70","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/art.22489","volume":"56","author":"AM Turkiewicz","year":"2007","unstructured":"Turkiewicz, A. M. & Moreland, L. W. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 56, 1051\u20131066 (2007).","journal-title":"Arthritis Rheum."},{"key":"6_CR71","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I","volume":"41","author":"K MacKay","year":"1998","unstructured":"MacKay, K., Mack, C., Brophy, S. & Calin, A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 41, 2263\u20132270 (1998).","journal-title":"Arthritis Rheum."},{"key":"6_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/35.4.373","volume":"35","author":"HL Averns","year":"1996","unstructured":"Averns, H. L. et al. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br. J. Rheumatol. 35, 373\u2013376 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"6_CR73","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers, M. C. et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann. Rheum. Dis. 64, 127\u2013129 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR74","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3899\/jrheum.080491","volume":"36","author":"E Lubrano","year":"2009","unstructured":"Lubrano, E. et al. Psoriatic Arthritis Spondylitis Radiology Index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J. Rheumatol. 36, 1006\u20131011 (2009).","journal-title":"J. Rheumatol."},{"key":"6_CR75","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/art.24425","volume":"61","author":"X Baraliakos","year":"2009","unstructured":"Baraliakos, X., Listing, J., Rudwaleit, M., Sieper, J. & Braun, J. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum. 61, 764\u2013771 (2009).","journal-title":"Arthritis Rheum."},{"key":"6_CR76","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/acr.22308","volume":"66","author":"BJ Biagioni","year":"2014","unstructured":"Biagioni, B. J. et al. Reliability of radiographic scoring methods in axial psoriatic arthritis. Arthritis Care Res. 66, 1417\u20131422 (2014).","journal-title":"Arthritis Care Res."},{"key":"6_CR77","first-page":"977","volume":"27","author":"E Lubrano","year":"2009","unstructured":"Lubrano, E. et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin. Exp. Rheumatol. 27, 977\u2013980 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"6_CR78","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann. Rheum. Dis. 68, 770\u2013776 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR79","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR80","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/annrheumdis-2012-201610","volume":"72","author":"P Richette","year":"2013","unstructured":"Richette, P. et al. Psoriasis and phenotype of patients with early inflammatory back pain. Ann. Rheum. Dis. 72, 566\u2013571 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR81","first-page":"S66","volume":"33","author":"RP Poggenborg","year":"2015","unstructured":"Poggenborg, R. P., Sorensen, I. J., Pedersen, S. J. & Ostergaard, M. Magnetic resonance imaging for diagnosing, monitoring and prognostication in psoriatic arthritis. Clin. Exp. Rheumatol. 33, S66\u2013S69 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"6_CR82","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/rheumatology\/keg475","volume":"43","author":"L Williamson","year":"2004","unstructured":"Williamson, L. et al. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology 43, 85\u201388 (2004).","journal-title":"Rheumatology"},{"key":"6_CR83","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.berh.2010.06.001","volume":"24","author":"M Ostergaard","year":"2010","unstructured":"Ostergaard, M., Poggenborg, R. P., Axelsen, M. B. & Pedersen, S. J. Magnetic resonance imaging in spondyloarthritis \u2014 how to quantify findings and measure response. Best Pract. Res. Clin. Rheumatol. 24, 637\u2013657 (2010).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"6_CR84","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/RHU.0000000000000558","volume":"23","author":"H Maldonado-Ficco","year":"2017","unstructured":"Maldonado-Ficco, H., Sheane, B. J., Thavaneswaran, A., Chandran, V. & Gladman, D. D. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change. J. Clin. Rheumatol. 23, 243\u2013245 (2017).","journal-title":"J. Clin. Rheumatol."},{"key":"6_CR85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3109\/03009742.2012.739637","volume":"42","author":"R Queiro","year":"2013","unstructured":"Queiro, R., Tejon, P., Alonso, S., Alperi, M. & Ballina, J. Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis. Scand. J. Rheumatol. 42, 220\u2013225 (2013).","journal-title":"Scand. J. Rheumatol."},{"key":"6_CR86","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.38050","volume":"65","author":"C Castillo-Gallego","year":"2013","unstructured":"Castillo-Gallego, C., Aydin, S. Z., Emery, P., McGonagle, D. G. & Marzo-Ortega, H. Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27. Arthritis Rheum. 65, 2274\u20132278 (2013).","journal-title":"Arthritis Rheum."},{"key":"6_CR87","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/rheumatology\/keu439","volume":"54","author":"RP Poggenborg","year":"2015","unstructured":"Poggenborg, R. P. et al. Head-to-toe whole-body MRI in psoriatic arthritis, axial spondyloarthritis and healthy subjects: first steps towards global inflammation and damage scores of peripheral and axial joints. Rheumatology 54, 1039\u20131049 (2015).","journal-title":"Rheumatology"},{"key":"6_CR88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun, J. et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70, 896\u2013904 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR89","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3899\/jrheum.141000","volume":"42","author":"S Rohekar","year":"2015","unstructured":"Rohekar, S. et al. 2014 update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J. Rheumatol. 42, 654\u2013664 (2015).","journal-title":"J. Rheumatol."},{"key":"6_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/acr.22708","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward, M. M. et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res. 68, 151\u2013166 (2016).","journal-title":"Arthritis Care Res."},{"key":"6_CR91","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper, J. et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann. Rheum. Dis. 76, 571\u2013592 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR92","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"6_CR93","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","volume":"76","author":"V Strand","year":"2017","unstructured":"Strand, V. et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann. Rheum. Dis. 76, 203\u2013207 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","volume":"3","author":"P Mease","year":"2016","unstructured":"Mease, P. & McInnes, I. B. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol. Ther. 3, 5\u201329 (2016).","journal-title":"Rheumatol. Ther."},{"key":"6_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02721966 (2017)."},{"key":"6_CR96","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 73, 817\u2013823 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR97","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","volume":"26","author":"N Yeremenko","year":"2014","unstructured":"Yeremenko, N., Paramarta, J. E. & Baeten, D. The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr. Opin. Rheumatol. 26, 361\u2013370 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"6_CR98","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"key":"6_CR99","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","volume":"72","author":"E Pathan","year":"2013","unstructured":"Pathan, E. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann. Rheum. Dis. 72, 1475\u20131480 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01583374 (2018)."},{"key":"6_CR101","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340\u20131347 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR102","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates, L. C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060\u20131071 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"6_CR103","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec, L. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75, 499\u2013510 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR104","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.3899\/jrheum.140877","volume":"41","author":"P Nash","year":"2014","unstructured":"Nash, P. et al. Updated guidelines for the management of axial disease in psoriatic arthritis. J. Rheumatol. 41, 2286\u20132289 (2014).","journal-title":"J. Rheumatol."},{"key":"6_CR105","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease, P. J. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50, 2264\u20132272 (2004).","journal-title":"Arthritis Rheum."},{"key":"6_CR106","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease, P. J. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279\u20133289 (2005).","journal-title":"Arthritis Rheum."},{"key":"6_CR107","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"PJ Mease","year":"2014","unstructured":"Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370, 2295\u20132306 (2014).","journal-title":"N. Engl. J. Med."},{"key":"6_CR108","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni, C. E. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52, 1227\u20131236 (2005).","journal-title":"Arthritis Rheum."},{"key":"6_CR109","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann. Rheum. Dis. 73, 1689\u20131694 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR110","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acr.22576","volume":"68","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh, A. et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res. 68, 267\u2013274 (2016).","journal-title":"Arthritis Care Res."},{"key":"6_CR111","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman, D. D. et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56, 476\u2013488 (2007).","journal-title":"Arthritis Rheum."},{"key":"6_CR112","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","volume":"73","author":"IB McInnes","year":"2014","unstructured":"McInnes, I. B. et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73, 349\u2013356 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR113","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3899\/jrheum.151404","volume":"43","author":"E Lubrano","year":"2016","unstructured":"Lubrano, E., Parsons, W. J. & Perrotta, F. M. Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J. Rheumatol. 43, 918\u2013923 (2016).","journal-title":"J. Rheumatol."},{"key":"6_CR114","first-page":"80","volume":"29","author":"E Lubrano","year":"2011","unstructured":"Lubrano, E. et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin. Exp. Rheumatol. 29, 80\u201384 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"6_CR115","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2017.1257939","volume":"13","author":"AB Maharaj","year":"2017","unstructured":"Maharaj, A. B. & Chandran, V. Treatment of psoriatic arthritis with traditional DMARD\u2019s and novel therapies: approaches and recommendations. Expert Rev. Clin. Immunol. 13, 319\u2013331 (2017).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"6_CR116","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","volume":"76","author":"SP Raychaudhuri","year":"2017","unstructured":"Raychaudhuri, S. P., Wilken, R., Sukhov, A. C., Raychaudhuri, S. K. & Maverakis, E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J. Autoimmun. 76, 21\u201337 (2017).","journal-title":"J. Autoimmun."},{"key":"6_CR117","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman, D. et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 377, 1525\u20131536 (2017).","journal-title":"N. Engl. J. Med."},{"key":"6_CR118","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/art.1780260210","volume":"26","author":"S Carette","year":"1983","unstructured":"Carette, S., Graham, D., Little, H., Rubenstein, J. & Rosen, P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 26, 186\u2013190 (1983).","journal-title":"Arthritis Rheum."},{"key":"6_CR119","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/art.1780230110","volume":"23","author":"RE Kaprove","year":"1980","unstructured":"Kaprove, R. E., Little, A. H., Graham, D. C. & Rosen, P. S. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum. 23, 57\u201361 (1980).","journal-title":"Arthritis Rheum."},{"key":"6_CR120","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/ard.2009.124206","volume":"69","author":"P Machado","year":"2010","unstructured":"Machado, P. et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann. Rheum. Dis. 69, 1465\u20131470 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR121","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/BOR.0b013e328352b7bd","volume":"24","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy, D. & Sieper, J. Radiographic progression in ankylosing spondylitis\/axial spondyloarthritis: how fast and how clinically meaningful? Curr. Opin. Rheumatol. 24, 363\u2013369 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"6_CR122","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063\u20133070 (2008).","journal-title":"Arthritis Rheum."},{"key":"6_CR123","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324\u20131331 (2008).","journal-title":"Arthritis Rheum."},{"key":"6_CR124","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde, D. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 68, 922\u2013929 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"6_CR125","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon, N. et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645\u20132654 (2013).","journal-title":"Arthritis Rheum."},{"key":"6_CR126","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. 77, 63\u201369 (2018).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0006-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T18:14:08Z","timestamp":1720289648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0006-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0006-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"11 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}